Hepatitis C screening for renal transplant candidates

HCV screening in kidney transplant candidates is not a single antibody test but a clinical decision pathway. It begins by establishing whether a candidate has been exposed to hepatitis C virus and whether infection is active, then extends to staging liver disease and assessing extrahepatic injury. Because active infection may coexist with clinically silent advanced fibrosis or cirrhosis, screening can determine whether a patient proceeds toward kidney transplantation alone, requires treatment before transplantation, or should be evaluated for simultaneous liver–kidney transplantation.

Purpose and Clinical Stakes

HCV infection is a systemic disease concept rather than a condition confined to the liver: it may produce autoimmune, dermatological, and renal disease, including cryoglobulinemia-associated vasculitis and glomerular injury. This broader impact makes screening especially important in chronic kidney disease, dialysis, and transplantation, where HCV has been associated with detrimental survival in both dialysis and transplant populations. Among kidney transplant candidates, chronic HCV prevalence has been reported from 7% to 40%, varying with geography and demographics; longer duration of end-stage renal disease, previous transplantation, black race, hepatitis B virus coinfection, and prior substance abuse are among the reported risk factors.

The immediate concern is often hidden liver damage. Biopsy studies have found advanced fibrosis in as many as 25% of candidates with active HCV infection, while another transplant evaluation reports stage 3 or 4 disease in 10%–25% of candidates. These patients may have well-compensated liver disease and no obvious clinical reason to be suspected of serious injury. Screening therefore converts an otherwise concealed risk into information that can shape transplant eligibility and treatment. Diabetes mellitus adds to the comorbidity burden: it is present in about 30% of HCV-infected candidates aged 30–50 years and reaches 63% among elderly candidates.

Testing for Exposure and Viremia

The diagnostic distinction is between anti-HCV antibodies, which indicate exposure, and HCV RNA, which establishes active infection. Third-generation enzyme-linked immunosorbent assay is used to detect anti-HCV antibodies. A positive antibody result alone cannot distinguish resolved infection from chronic infection; that distinction depends on detecting HCV RNA in serum with a sensitive molecular assay, whose threshold is approximately 15 IU/ml. Chronic infection is established by the combination of anti-HCV positivity and detectable HCV RNA, with active chronic infection defined by persistence for more than six months.

The order of testing depends on the prevalence of HCV in the surrounding community. In low-prevalence regions, candidates are initially tested with enzyme immunoassay, and those with positive results undergo nucleic acid testing to confirm viremia. In high-prevalence settings, nucleic acid testing is recommended as the first-line screen because a negative enzyme immunoassay cannot reliably exclude infection. The same logic applies to people already placed on the kidney waiting list who were never tested before listing: a positive antibody test in a low-prevalence region requires nucleic acid confirmation, whereas testing can proceed directly to nucleic acid testing in a high-prevalence setting.

This sequence prevents two opposite errors. Treating antibody positivity as proof of ongoing infection would misclassify people who have cleared the virus, while relying on antibody negativity in a high-prevalence setting could miss active infection. The screening pathway thus separates exposure status from virologic activity before decisions about antiviral therapy, transplantation, and follow-up are made.

Extending Screening to Organ Injury

A positive nucleic acid test triggers more than a virologic label. Candidates with active HCV infection require evaluation of hepatic and extrahepatic effects, including cryoglobulinemia-associated vasculitis. Liver injury is staged by liver biopsy or noninvasive testing. Biochemical tools such as Fibrotest, Fibrometre, Hepascore, Forns index, and Fib-4, together with elastometry by FibroScan, can reduce the need for approximately half of liver biopsies and permit yearly fibrosis follow-up in untreated patients. Nevertheless, liver biopsy remains the gold standard in the pretransplant evaluation and should be obtained in patients determined to have active HCV infection.

The extrahepatic assessment matters because HCV is the major cause of mixed cryoglobulinemia, a systemic vasculitis that may involve arthralgias, arthritis, Raynaud phenomena, purpura, peripheral neuropathy, hypocomplementemia, and kidney disease. Renal manifestations range from non-nephrotic or nephrotic proteinuria and hematuria to reduced estimated glomerular filtration rate; acute nephritic syndrome and nephrotic syndrome are reported clinical presentations in 25% and 20% of affected patients, respectively. Purpura, arthralgias, or neuropathy may precede kidney disease by several years, so the absence of renal symptoms does not remove the need for a broader assessment.

The screening process also distinguishes HCV-related renal disease from post-transplant complications that may later resemble it. HCV-infected renal allograft recipients are prone to immune complex-mediated glomerulonephritis, including de novo membranoproliferative glomerulonephritis associated with type II mixed cryoglobulinemia. Such disease may present with hypertension, microhematuria, proteinuria, renal dysfunction, or nephrotic syndrome. Identifying active infection and renal involvement before transplantation establishes a baseline against which later allograft abnormalities can be interpreted.

Consequences for Treatment and Transplant Eligibility

There is no universal consensus on treating every viremic candidate before transplantation, but the screening result creates the basis for an individualized plan. Antiviral treatment in the period covered by the source was principally based on pegylated interferon and ribavirin, with direct-acting antiviral drugs such as telaprevir or boceprevir added for genotype 1 infection. Sustained virologic response represents virologic recovery and, in the absence of liver comorbidities, may be accompanied by fibrosis remodeling. More than half of patients with chronic infection achieved sustained virologic response with pegylated interferon and ribavirin, although genotype 1 remained harder to treat; first-generation protease-inhibitor triple therapy increased sustained virologic response rates by approximately 20%–30% in genotype 1 infection.

The potential value of pretransplant viral clearance extends beyond the liver. Evidence was described as limited and partly anecdotal, but sustained virologic response before transplantation might reduce the risk of post-transplant diabetes and immune complex-mediated glomerular disease in the allograft. Most patients who achieve sustained virologic response before transplantation do not relapse after immunosuppression is introduced. By contrast, post-transplant interferon treatment has been associated with increased allograft rejection, so efforts to eradicate HCV are preferably concentrated before transplantation.

Candidates with established or decompensated cirrhosis should be referred to a liver transplant team for consideration of simultaneous liver–kidney transplantation rather than proceeding automatically to kidney-alone transplantation. The screening result therefore acts as a gatekeeping mechanism: it can support kidney-alone transplantation, prompt antiviral therapy and reassessment, or redirect the candidate toward combined-organ evaluation.

Waiting-List Surveillance and Institutional Policy

Screening does not end when a candidate is listed. Because deceased-donor waiting times in some areas of the United States approach five to seven years, HCV-infected candidates require continuing surveillance to ensure that they remain suitable for kidney transplantation. Candidates who were known to be infected before transplantation and achieved sustained virologic response should undergo nucleic acid testing at least annually to confirm that the response remains durable. Relapse warrants hold status and referral to a hepatologist for consideration of retreatment.

Candidates who remain viremic should receive annual evaluation for progression of liver disease. In one group of candidates who underwent repeat liver biopsy while still waiting, 8 of 13, or 62%, showed worsening liver histology. This contrasted with follow-up biopsies after transplantation, in which only 7 of 31, or 23%, showed interval worsening. For candidates whose initial biopsy demonstrates Metavir stage 1 or 2 fibrosis, repeat biopsy every five years was recommended; stage 3 fibrosis calls for closer reassessment, at three years. Progression to early or established cirrhosis should lead to removal from the kidney waiting list and referral to a liver team for consideration of simultaneous liver–kidney transplantation.

The screening pathway thus links laboratory classification to the administration of scarce organs. It does not merely name an infection: it determines who requires specialist review, who may need treatment before an operation, who needs repeated assessment while waiting, and who must be redirected toward combined-organ transplantation. In that sense, HCV screening is both a diagnostic practice and a mechanism for managing transplant risk, timing, and eligibility.